Investors

Nautilus is a biotechnology company developing a proteomics platform that aims to deliver superior sensitivity more quickly, more completely, and less expensively than is currently possible.

Nautilus Biotechnology aims to enable a dramatic acceleration of basic science research, significantly improve the success rate of therapeutic development, and enhance opportunities for personalized and predictive medicine. Nautilus’ corporate headquarters is in Seattle, Washington and scientific research and development is being conducted from its San Carlos, California office and labs.